The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Sally Thomas(Sheffield Teaching Hospitals NHS Foundation Trust), Sarah Danson(Weston Park Cancer Centre)
Cited by 638
Related Papers
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
|British Journal of Cancer|2023|36
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
|Journal of Clinical Oncology|2019|31
Genetic and chemical modulators of JAK/STAT signalling in cancer
|White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)|2015|0